Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiotherapy plus chemotherapy versus chemotherapy alone for resectable gastric cancer
ACTRN12609000035224Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Sep 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin, fluorouracil, capecitabine, oxaliplatin and 2 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Overall survival. Started Sep 2009; status: completed.
02
Drugs
epirubicincisplatinfluorouracilcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ACTRN12609000035224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000035224.